Partial nephrogenic diabetes insipidus associated with lithium therapy
- PMID: 31494590
- PMCID: PMC6731909
- DOI: 10.1136/bcr-2019-231093
Partial nephrogenic diabetes insipidus associated with lithium therapy
Corrected and republished in
-
Republished: Partial nephrogenic diabetes insipidus associated with lithium therapy.Drug Ther Bull. 2020 Mar;58(3):45-47. doi: 10.1136/dtb.2019.231093rep. Epub 2019 Nov 29. Drug Ther Bull. 2020. PMID: 31784466 No abstract available.
Abstract
A 40-year-old Caucasian man developed excessive thirst and polyuria particularly at night over the preceding 6 months. He had been taking lithium for 16 years for the treatment of bipolar affective disorder. Investigations revealed subnormal maximum urinary concentrating ability after 8 hours of water deprivation and only a borderline response of urine osmolality to exogenous desmopressin given by intramuscular injection. A plasma copeptin concentration was elevated at 23 pmol/L. These results were consistent with partial nephrogenic diabetes insipidus. He was encouraged to increase his water intake as dictated by his thirst. In addition, he received amiloride with some improvement in his symptoms. Clinicians should be aware of the risk of nephrogenic diabetes insipidus with long-term lithium use and seek confirmation by a supervised water deprivation test augmented with a baseline plasma copeptin. If increased water intake is insufficient to control symptoms, amiloride may be considered.
Keywords: drugs: endocrine system; fluid electrolyte and acid-base disturbances.
© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride.Clin J Am Soc Nephrol. 2008 Sep;3(5):1324-31. doi: 10.2215/CJN.01640408. Epub 2008 Jul 2. Clin J Am Soc Nephrol. 2008. PMID: 18596116 Free PMC article. Clinical Trial.
-
Persistent nephrogenic diabetes insipidus following lithium therapy.Scott Med J. 1997 Feb;42(1):16-7. doi: 10.1177/003693309704200106. Scott Med J. 1997. PMID: 9226773
-
Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F669-F676. doi: 10.1152/ajprenal.00147.2017. Epub 2017 Jun 14. Am J Physiol Renal Physiol. 2017. PMID: 28615247
-
Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs.Ren Fail. 1997 Jan;19(1):183-8. doi: 10.3109/08860229709026274. Ren Fail. 1997. PMID: 9044466 Review.
-
Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.Am J Kidney Dis. 1987 Nov;10(5):329-45. doi: 10.1016/s0272-6386(87)80098-7. Am J Kidney Dis. 1987. PMID: 3314489 Review.
Cited by
-
Ifosfamide-Induced Partial Arginine Vasopressin Resistance Responsive to Vasopressin/Desmopressin and Amiloride.Cureus. 2025 May 11;17(5):e83897. doi: 10.7759/cureus.83897. eCollection 2025 May. Cureus. 2025. PMID: 40497202 Free PMC article.
-
A Rare Case of Lithium-induced Partial Nephrogenic Diabetes Insipidus.Cureus. 2020 Apr 28;12(4):e7877. doi: 10.7759/cureus.7877. Cureus. 2020. PMID: 32489731 Free PMC article.